Ученые разработали метод наблюдения за движением лекарств внутри живых раковых клеток в реальном времени

Live-cell imaging shows how drugs move inside cancer cells and how cellular responses change over time during cancer drug research - Live-cell imaging tracks drug movement inside living cancer cells - SRS imaging detects the experimental drug through its chemical signal without a fluorescent label - Drug responses can be followed over time rather than only at a final test point The research does not show a new cancer treatment. Instead, it demonstrates a way to watch drug-cell interactions unfold over time, giving researchers a closer look at cancer biology in motion (1✔ ✔Trusted Source Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system Go to source). What Is Live-Cell Imaging in Cancer Research? Live-cell imaging means observing cells while they are alive. Scientists can repeatedly image the same cells or cell population to see how they change after exposure to a drug. SRS microscopy is a type of Raman imaging. It uses light to detect chemical information from molecules. In this study, SRS imaging detected the experimental drug 7RH through its chemical signal without requiring a fluorescent label. A separate peer-reviewed methods paper has also demonstrated a chamber designed for time-lapse SRS imaging of living cells (2✔ ✔Trusted Source A Flexible Chamber for Time-Lapse Live-Cell Imaging with Stimulated Raman Scattering Microscopy Go to source). This approach can provide information about what happens during treatment rather than showing only what the cells look like at the end of an experiment. How Does Live-Cell Imaging Track Cancer Drugs? The main study examined 7RH, an experimental inhibitor of discoidin domain receptor 1 (DDR1). DDR1 is a cell-surface protein involved in how cells interact with their surrounding environment. The researchers used an alkyne group within 7RH as a chemical signal that could be detected using Raman imaging. This allowed them to identify the experimental drug inside living cells and observe where it accumulated. In MCF-7 breast cancer cells, 7RH was detected mainly in the cytoplasm, the part of the cell outside the nucleus. At a concentration of 5 μM, the drug was detected inside the cells within 30 minutes, and its intracellular signal continued to increase over 24 hours. At two hours, significant intracellular accumulation was detected at concentrations above 500 nM (1✔ ✔Trusted Source Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system Go to source). Which Cancer Cells Were Tested in the Live-Cell Study? Researchers tested four cultured cancer-cell models: MCF-7 and MDA-MB-231 breast cancer cells, HCT 116 colorectal cancer cells and A549 lung cancer cells. More than 25 cells from each cell line were used for comparative uptake measurements. 7RH uptake was detected in all four models after two hours of treatment. The researchers also found that drug uptake did not appear to depend on the level of DDR1 expression in the cell models tested (1✔ ✔Trusted Source Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system Go to source). The researchers also measured cell viability. In MCF-7 cells, the reported IC50 for 7RH was approximately 1.84 μM. IC50 means the concentration of a substance that produces 50% inhibition of a measured biological response under defined laboratory conditions. It is not a recommended human treatment dose. Can Live-Cell Imaging Show What Happens During Cancer Drug Treatment? One important feature of the research was a perfusion chamber. It allowed researchers to repeatedly treat and image the same living cell population during an experiment. In MCF-7 cells, SRS images were collected at two-minute intervals after exposure to 7RH. The researchers also examined 7RH together with cisplatin in A549 lung cancer cells. The cells received 1 μM 7RH and 5 μM cisplatin, and drug uptake was followed using time-lapse imaging. Cell viability was later assessed after 72 hours using an Alamar Blue assay. This experiment used 12 samples (1✔ ✔Trusted Source Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system Go to source). The researchers also studied cellular adhesion and migration. At concentrations above 5 μM, 7RH treatment was associated with more than a 50% reduction in cellular adhesion in MCF-7 and MDA-MB-231 cells compared with controls. A scratch-wound experiment also showed reduced movement of MCF-7 cells after treatment. These were observations in cultured cells and do not demonstrate that 7RH treats cancer in people (1✔ ✔Trusted Source Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system Go to source). What Could Live-Cell Imaging Add to Cancer Drug Discovery? The main research value of this approach is its ability to follow drug uptake and cellular changes over time. Researchers can see where an experimental compound goes and observe what happens to cells during treatment rather than relying only on a final measurement. This could be useful during early drug research, particularly when the timing and location of drug uptake are important. The study authors described the approach as potentially useful for phenotypic imaging during the preclinical stage of drug development (1✔ ✔Trusted Source Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system Go to source). But the evidence has clear limits. The experiments were performed in cultured cells, not in patients. The research did not show that SRS imaging improves cancer survival, diagnosis or treatment response. It also did not establish 7RH as a cancer medicine. The reported 1.84 μM IC50 is a laboratory result under specific experimental conditions. It should not be interpreted as a dose that could be given safely or effectively to a person. What Does Live-Cell Imaging Mean for Cancer Patients? For patients and families, the most important message is simple: this research does not provide a new cancer treatment today. There is no reason to start, stop or change cancer treatment because of these findings. The potential benefit is further upstream, in the laboratory. If this type of imaging continues to prove useful, it could give researchers a more detailed picture of how experimental drugs behave inside cells before potential therapies move through later stages of development. For now, patients can benefit indirectly by understanding the difference between an early laboratory finding and a proven treatment. A drug that changes cultured cancer cells is not automatically a drug that will work safely or effectively in people. Cancer research advances through many complementary approaches, including prevention, early detection, better laboratory models and carefully tested treatments. Live-cell imaging is one research tool that may help scientists understand what happens inside cancer cells with greater detail. Why Watching Cancer Cells Live Could Improve Future Drug Research The most important message from this research is not that a new cancer cure has been found. It is that scientists have demonstrated a way to watch an experimental drug move through living cancer cells and follow cellular responses over time. That closer view can help researchers ask a more detailed question: not simply whether a drug changes a cell, but when the drug enters, where it goes and how the cell responds as treatment continues. The approach still needs further validation and cannot replace clinical research. But it offers a valuable research perspective: seeing cancer-cell biology as a process rather than only as a final snapshot. For patients, that means there is no new treatment to act on today. For scientists, it means another window into the complex behavior of living cancer cells. That distinction keeps the research in perspective while showing why better ways to observe cancer biology could contribute to the development of future treatments. Frequently Asked Questions Q: What Is Live-Cell Imaging? A: Live-cell imaging allows scientists to observe living cells repeatedly over time instead of examining only one final stage. Q: How Does Live-Cell Imaging Help Cancer Research? A: It helps researchers study how cancer cells respond to experimental drugs, including where drugs go inside cells and how cellular behavior changes. Q: What Is Raman Imaging? A: Raman imaging uses light to obtain chemical information from molecules. Stimulated Raman scattering microscopy is a Raman-based method that can be used for live-cell imaging. Q: What Drug Was Studied Using Live-Cell Imaging? A: The study examined 7RH, an experimental inhibitor of DDR1. It was tested in cultured cancer-cell models and is not an established cancer treatment. Q: Can Live-Cell Imaging Treat Cancer? A: No. Live-cell imaging is a research method. The study did not show that the technology can diagnose or treat cancer in patients. - Temporal imaging of drug dynamics in live cells using stimulated Raman scattering microscopy and a perfusion cell culture system† - (https://pubs.rsc.org/cb/article/3/9/1154/1261408/Temporal-imaging-of-drug-dynamics-in-live-cells) - A Flexible Chamber for Time-Lapse Live-Cell Imaging with Stimulated Raman Scattering Microscopy - (https://www.jove.com/t/64449/a-flexible-chamber-for-time-lapse-live-cell-imaging-with-stimulated) Source-Medindia